Compare · NVCR vs RMD
NVCR vs RMD
Side-by-side comparison of NovoCure Limited (NVCR) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVCR and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $28.57B, about 14.3x NVCR ($2.00B).
- Over the past year, NVCR is down 6.1% and RMD is down 22.0% - NVCR leads by 15.8 points.
- NVCR has been more active in the news (18 items in the past 4 weeks vs 7 for RMD).
- Both have 25 recent analyst ratings on file.
- Company
- NovoCure Limited
- ResMed Inc.
- Price
- $17.26+2.49%
- $196.95+1.94%
- Market cap
- $2.00B
- $28.57B
- 1M return
- -3.47%
- -4.76%
- 1Y return
- -6.14%
- -21.97%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 18
- 7
- Recent ratings
- 25
- 25
NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest NVCR
- NovoCure Limited filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Stafford Kristin was granted 11,610 units of Ordinary Shares, increasing direct ownership by 103% to 22,934 units (SEC Form 4)
- Chief Executive Officer Leonard Frank X sold $614,635 worth of Ordinary Shares (34,273 units at $17.93), decreasing direct ownership by 7% to 459,520 units (SEC Form 4) (withholding tax)
- Director Leung Gabriel was granted 11,610 units of Ordinary Shares, increasing direct ownership by 13% to 101,109 units (SEC Form 4)
- Director Ocean Allyson J was granted 11,610 units of Ordinary Shares, increasing direct ownership by 103% to 22,934 units (SEC Form 4)
- Director Scannell Timothy J was granted 11,610 units of Ordinary Shares, increasing direct ownership by 81% to 25,898 units (SEC Form 4)
- Director Hilleman Jeryl L was granted 11,610 units of Ordinary Shares, increasing direct ownership by 84% to 25,471 units (SEC Form 4)
- Director Hung David was granted 11,610 units of Ordinary Shares, increasing direct ownership by 57% to 32,075 units (SEC Form 4)
- Director Madden Martin J. was granted 11,610 units of Ordinary Shares, increasing direct ownership by 62% to 30,284 units (SEC Form 4)
- Director Vernon W Anthony was granted 11,610 units of Ordinary Shares, increasing direct ownership by 6% to 209,267 units (SEC Form 4)
Latest RMD
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $968,064 worth of ResMed Common Stock (4,991 units at $193.96) as part of a pre-agreed trading plan, increasing direct ownership by 0.01% to 466,256 units (SEC Form 4)
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)
- Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
- Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
- SEC Form SD filed by ResMed Inc.
- Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
- Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,037,233 worth of ResMed Common Stock (4,991 units at $207.82) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 3 filed by new insider Bloomer Aaron
- SEC Form 4 filed by Chief Financial Officer Sandercock Brett